Albert B. Sabin Vaccine Institute, Inc. (The)
Washington, DC Part of Sabin, Albert B Vaccine Instit
- UEI
- H5E8NU6N2HZ5
- CAGE
- 5MPW2
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
FNYDNUKJJL17
-
Parent
FNYDNUKJJL17
- SAM.gov registration date
- Physical address
- 2000 Pennsylvania Ave NW #7000, Washington, DC 20006, USA
- Website
- sabin.org
- Founded
- 1993
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Financials
- Diversified Financials
- Capital Markets
- Fundraising
- SIC code
- 83 Social Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $261,929,856 |
| FY2025 | $70,386,301 |
| FY2024 | $20,310,632 |
| FY2023 | $116,551,404 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $261,929,856 |
Contract awards
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Mapp Biopharmaceutical, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Medigen, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Reithera S.R.L. | Castel Romano, Lazio | 325414 Biological Product (except Diagnostic) Manufacturing |
| Auro Vaccines LLC | Pearl River, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Seqirus Inc. | Holly Springs, NC | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Albert B. Sabin Vaccine Institute, Inc. (doing business as Sabin Vaccine Institute) is a non-profit organization based in Washington, DC, that develops, manufactures, and procures vaccines against emerging infectious disease threats as a prime federal contractor. The vendor operates exclusively as a prime (100% of recent awards) with no set-aside designations, competing full-and-open across biotech research and development and advanced medical countermeasures work.
All six recent awards concentrate with the Department of Health and Human Services — three awards totaling $1.43 billion through the Office of the Assistant Secretary for Preparedness and Response (ASPR), two through the Centers for Disease Control and Prevention, and one through the National Institutes of Health. The top customer by volume and potential value is ASPR, which funds the vendor's filovirus vaccine programs. Sabin is a child entity under parent company Sabin, Albert B Vaccine Instit.
The vendor's primary federal work targets advanced development and licensure of medical countermeasures against material health threats. Sabin holds two major ASPR contracts: a $1.042 billion definitive cost-plus-fixed-fee contract awarded May 8, 2026 (extending through April 30, 2036) for advanced development, licensure, and procurement of vaccines against Marburg virus and Sudan ebolavirus under the Strategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP) program, and a $238.4 million definitive cost-plus-fixed-fee contract awarded December 29, 2022 (period of performance through September 30, 2030) for manufacture of Sudan Ebolavirus vaccine bulk drug substance and final drug product. The ASPR Marburg contract addresses a government-identified requirement for 2.9 million doses of Marburg vaccine and 1.13 million doses of Sudan ebolavirus vaccine for post-exposure prophylaxis; no FDA-licensed vaccines currently exist for either Sudan ebolavirus or Marburg virus. Sabin also holds a Cooperative Agreement with the CDC's Center for Global Health (awarded September 30, 2024, extending through September 29, 2029) for strengthening immunization program implementation in vulnerable sub-national areas of Brazil, increasing vaccination coverage and disease surveillance in partnership with Brazil's National Immunization Program.
Activity across the portfolio is sparse — one award per year spanning 2016–2026 — but dollar-heavy. One award (combined potential value $149.7 million) faces ultimate completion within the next twenty-four months and therefore recompete exposure in that window. Service Contract Inventory data shows SCI-reportable invoiced revenue of $25.4 million in FY2024 across 8.6 FTEs on prime contracts, with government-paid median hourly rates around $223/hr. Across SCI-reportable prime contracts, subcontractors perform 34% of contractor hours, with 29 named subcontractors reported in the dataset.
Quick answers
Is Albert B. Sabin Vaccine Institute, Inc. (The) registered in SAM.gov?
Yes. Albert B. Sabin Vaccine Institute, Inc. (The)'s SAM.gov registration is active through April 6, 2027.
How much has Albert B. Sabin Vaccine Institute, Inc. (The) received in federal contracts?
Federal contracts obligated $70,386,301 to Albert B. Sabin Vaccine Institute, Inc. (The) in fiscal year 2025 and $469,178,193 in fiscal years 2023 through 2027.
How does Albert B. Sabin Vaccine Institute, Inc. (The) rank among federal contractors?
Albert B. Sabin Vaccine Institute, Inc. (The) ranked #3 in NAICS 541714, #3 in PSC AN42 and #9 in PSC AN in FY2025.
What is Albert B. Sabin Vaccine Institute, Inc. (The)'s most recent federal award?
Albert B. Sabin Vaccine Institute, Inc. (The)'s most recent federal contract award is Strategic marburg advanced research and development, preparedness, registration, evaluation and procurement (smart-prep) (75A50126C00001), from Office of the Assistant Secretary for Preparedness and Response, on May 8, 2026.
On GovTribe
See Albert B. Sabin Vaccine Institute, Inc. (The)'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors